BHC Stock Analysis: Buy, Sell, or Hold?
BHC - Bausch Health Companies Inc
$4.96
-0.03 (-0.60%)
▼
5d:
-4.06%
30d:
-8.49%
90d:
-4.25%
HOLD
MODERATE Confidence
Analysis Updated: Jun 16, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Smart Money Distribution
None View Scanner →
Strength: 6.1/10
Get Alerted When BHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BHC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: BHC shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.80
Based on -0.3% avg growth
INTRINSIC VALUE TODAY
$3.60
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BHC is currently trading at $4.96, which is considered oversold relative to its 30-day fair value range of $5.10 to $5.48. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.2) compared to its historical average (1.4). Remarkably, the market is currently pricing in an annual earnings decline of 6.4% over the next few years. This pessimistic expectation contrasts with the company's recent 1368.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BHC is in a strong uptrend. The price is currently testing key support at $4.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BHC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.40 (+49.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BHC is in a strong uptrend. The price is currently testing key support at $4.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BHC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.40 (+49.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.10 -
$5.48
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding BHC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 49.2% below Wall St target ($7.40)
Trading Range Analysis
30-Day Trading Range
$5.10 -
$5.48
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.89
Resistance Level
$5.39
Current Trend
Strong Uptrend
Technical data as of
Jun 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.18
Wall Street Target
$7.40
(+49.2%)
Revenue Growth (YoY)
11.7%
Earnings Growth (YoY)
1368.0%
Profit Margin
-11.5%
Valuation Discount vs History
-6.4% cheaper
PE vs Historical
1.2 vs 1.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.4%
(market-implied from PE analysis)
1-Year Target
$4.64
(-6%)
2-Year Target
$4.35
(-12%)
3-Year Target
$4.07
(-18%)
3-Yr Target (if PE normalizes)
(PE: 1→1)
$4.84
(-2%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: -4.6%)
$79.75
(+1508%)
Base:
(SPY PE: 1.2, Growth: -4.6%)
$4.31
(-13%)
Bear:
(PE: 1.0, Growth: -4.6%)
$3.66
(-26%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.2 to 1.4
Stabilization Target:
$5.90
(+19.0%)
PE Expansion Potential:
+19.0%
Share & Embed Analysis
Last updated: June 16, 2026 5:12 PM ET
Data refreshes hourly during market hours. Next update: 6:12 PM
Data refreshes hourly during market hours. Next update: 6:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$193 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 57 HOLD |
Advanced BHC Option Strategies
Professional options setups generated by AI based on today's BHC price and gamma walls.
